The medication is applied to address symptoms related to physical discomfort and is used for managing moderate-to-severe pain that is expected to last for an extended duration. It is commonly used when pain is not adequately controlled by other standard approaches and the patient requires continuous, around-the-clock, long-term support. It is generally relevant in conditions presenting with systemic or localized discomfort, such as certain chronic back conditions, osteoarthritis-related pain, or cancer-related discomfort.

“The extended-release formulation generally contributes to around-the-clock symptom management, which helps maintain a sense of stability when symptoms are more noticeable.”

Continuous Analgesia and Symptom Stability

The key therapeutic function is to provide sustained symptomatic support for the management of unremitting daily pain. The extended-release formulation helps ease the overall symptom burden by supporting a continuous, steady level of relief, which assists with maintaining functional stability during prolonged symptomatic periods. This is applied when groups of symptoms, marked by increased discomfort or tension, become difficult to manage.

---

Quick Fact: Relief for Persistent Pain

The medication is commonly used to help with severe, chronic pain that necessitates scheduled, around-the-clock symptomatic assistance for an extended period.

Official Eligibility and Contraindications

Opana ER (oxymorphone hydrochloride) is an extended-release opioid analgesic indicated only for adults with moderate to severe pain that requires daily, around-the-clock, long-term treatment when alternative non-opioid options are inadequate. It is not for as-needed, mild, acute, or short-duration pain.

Populations for Whom Use is Prohibited (Contraindicated):

• Patients with significant respiratory depression or acute or severe bronchial asthma in an unmonitored setting.
• Individuals with moderate or severe hepatic (liver) impairment.
• Patients with known or suspected gastrointestinal obstruction, including paralytic ileus.
• Patients with a known hypersensitivity to oxymorphone or to morphine analogs (e.g., codeine).

Populations Requiring Special Consideration or Restricted Use:

• Elderly, cachectic, or debilitated patients are at increased risk for life-threatening respiratory depression and require close monitoring and potential dose reduction.
• Patients with mild hepatic impairment or renal (kidney) impairment (Creatinine Clearance < 50 mL/min) require a reduced starting dose and careful titration.
• Use in pregnant women may result in Neonatal Opioid Withdrawal Syndrome (NOWS). Use is generally not recommended while lactating.
• Patients must not consume alcohol or use products containing alcohol while on Opana ER therapy.

The interaction profile for Opana ER is defined by mandated restrictions concerning pharmacodynamic potentiation and pharmacokinetic modifications. All documented interactions are based on official government regulatory sources.

Contraindicated and High-Risk Combinations

Opana ER is formally documented as contraindicated with Monoamine Oxidase Inhibitors (MAOIs), including use within 14 days of discontinuing MAOI treatment. Co-ingestion of alcohol (ethanol-containing products) is strictly prohibited. This restriction is based on a documented pharmacokinetic interaction where alcohol significantly increases oxymorphone plasma concentrations, raising the risk of fatal overdose.

Pharmacodynamic and Exposure-Altering Interactions

Co-administration with Central Nervous System (CNS) depressants, such as benzodiazepines, sedatives, or other opioid analgesics, carries an officially documented pharmacodynamic risk. This additive effect can result in severe outcomes, including profound sedation and respiratory depression. Additionally, combining the medication with Anticholinergics increases the risk of severe constipation or paralytic ileus. The use of mixed agonist/antagonist opioids is documented to potentially reduce the analgesic effect or precipitate withdrawal symptoms.

Administration Constraints and Population Considerations

A timing-based restriction is in effect for food. Since co-administration with food increases oxymorphone exposure, the official label requires that Opana ER must be administered on an empty stomach, defined as at least one hour before or two hours after eating. Regulatory documents also note that patients with mild hepatic impairment or renal impairment may experience higher oxymorphone plasma concentrations, requiring specific caution.

Mu-Opioid Receptor Agonism

The mechanism of action involves oxymorphone (the active substance) acting as an agonist at the mu-opioid receptors (mu-OR), which are defined biological targets located within the central nervous system. This molecular interaction initiates a G-protein signaling cascade within neurons. The activation of the mu-OR results in the inhibition of adenylyl cyclase and influences ion channel conductance, promoting the efflux of potassium and inhibiting the influx of calcium ions.

---

Modulation of Nociceptive Transmission Pathways

By modulating ion channel activity, oxymorphone decreases the excitability of the postsynaptic neuron and limits the presynaptic release of excitatory neurotransmitters involved in signal transmission. This effect is exerted on the ascending nociceptive pathways in the spinal cord and in higher brain centers, altering the flow of neuronal messages. The outcome is a dampening of activity within dysregulated signaling pathways.

---

Sustained Mechanistic Engagement

Opana ER (Extended Release) is a formulation that controls the rate at which oxymorphone is released into the systemic circulation over approximately 12 hours. This sustained delivery ensures that the drug maintains a steady concentration, resulting in prolonged and sustained engagement of the mu-ORs throughout the dosing interval. This steady activity supports continuous receptor modulation.

How to Use Opana ER: Official Administration Guidelines

Opana ER (oxymorphone extended-release) is a long-acting opioid analgesic, and its administration must strictly follow the structured protocol to ensure the proper release of the medication and maintenance of stable concentrations.

Administration and Frequency

The approved route of administration for Opana ER is oral. The medication is scheduled for twice-daily use (every 12 hours) to provide continuous, around-the-clock pain management. The standard starting dose for an opioid-naïve adult is 5 mg every 12 hours. Dose adjustments, known as titration, are typically made gradually, in increments of 5 mg to 10 mg every 12 hours, with an interval of 3 to 7 days between adjustments to allow the patient's body to reach a stable state.

Essential Administration Conditions

Condition	Administration Instruction
Timing in Relation to Meals	Must be administered on an empty stomach, specifically at least 1 hour prior to or 2 hours after eating, as food significantly impacts absorption.
Tablet Integrity	The tablets must be swallowed whole with sufficient water to ensure complete swallowing. They must not be broken, chewed, dissolved, or crushed under any circumstance.

Population-Specific Dosing

Patients with known renal impairment (CrCl < 50 mL/min) or mild hepatic impairment require a conservative approach to initiation. The starting dose for these populations is typically 5 mg every 12 hours for opioid-naïve patients, or a 50% reduction in the starting dose if the patient is converting from another opioid regimen. The elderly should also initiate dosing at the lowest available strength.

Discontinuation and Missed Doses

If a dose is missed, the patient should take the next dose at the next regularly scheduled time; a double dose should not be taken to compensate. For long-term use, therapy must be tapered gradually to prevent the onset of withdrawal symptoms.

Opana ER: Recent Clinical Evidence

Clinical studies involving Opana ER (oxymorphone extended-release) have primarily focused on its use for managing moderate to severe chronic pain in adult patients. The evidence base includes double-blind, randomized, placebo-controlled trials in populations with conditions such as chronic low back pain and osteoarthritis.

Efficacy Data

Research has shown that, in studies using an enriched-enrollment randomized-withdrawal design, Opana ER treatment resulted in significantly smaller increases in pain intensity scores (measured by the Visual Analog Scale or VAS) compared to placebo in patients who had previously responded to the drug. For instance, in one 12-week study involving opioid-experienced patients with chronic low back pain, patients continuing Opana ER demonstrated a significantly lower increase in pain scores from the randomization baseline compared to those randomized to placebo. This suggests that the analgesic effects were maintained for the duration of the trial period in the population studied.

Comparative trials have also evaluated oxymorphone ER against other opioid formulations, such as controlled-release oxycodone and controlled-release morphine. In these comparisons, Opana ER demonstrated comparable analgesic effects in patients with chronic pain.

Tolerability and Long-Term Data

Studies suggest that Opana ER is generally well-tolerated in patients who successfully complete the dose titration process. The most frequently reported adverse events in clinical trials were typical of opioid analgesics, including nausea, constipation, and somnolence. Long-term, open-label extension studies, lasting up to 52 weeks in some cases, observed that the pain relief achieved during the initial study was sustained over time in the continuing patient population, with minimal dose escalation required for many.

Due to its classification and risks, research continues to emphasize the importance of careful patient selection and monitoring, particularly regarding the risk of misuse and abuse associated with the oxymorphone opioid class.

Common questions about Opana ER (FAQ)

Q: Is Opana ER considered a primary pain treatment option, or is it reserved for specific cases?

Regulatory documents state that Opana ER is indicated only for managing moderate to severe pain that requires continuous, around-the-clock opioid treatment for an extended time. It is generally reserved for use when other alternative, non-opioid treatments have been determined to be inadequate. This classification means it is not used for pain that can be managed on an 'as-needed' basis.

Q: Is it normal to see part of the Opana ER tablet in my stool?

Official information indicates that the tablet is manufactured using an extended-release matrix which is designed to slowly release the active medicine (oxymorphone) over a long period. This inert matrix is not absorbed by the body and may pass into the stool after the medicine has been released. Official information emphasizes that the tablet is required to be swallowed whole to function correctly.

Q: What happens if an Opana ER tablet is accidentally broken or chewed?

The official Boxed Warning states that breaking, chewing, crushing, or dissolving the tablet results in the rapid release of the entire dose of oxymorphone. This rapid absorption could lead to dangerously high concentrations of the medication in the body, which carries the risk of a fatal overdose.

Q: What are the potential long-term effects of taking Opana ER?

Studies and official product information indicate that long-term use of opioid analgesics may be associated with certain effects. These include the potential for developing analgesic tolerance, which means the body may need a higher dose over time to achieve the same level of pain relief. Additionally, long-term use has been linked to decreased sex hormone levels (androgen deficiency).

Q: Does Opana ER have a risk of causing a condition called Serotonin Syndrome?

Official product warnings indicate a risk of developing Serotonin Syndrome when Opana ER is used alongside other medicines that affect the chemical serotonin in the brain. Serotonin Syndrome is a rare but potentially serious condition. This interaction is primarily seen when combining the medication with certain other drugs, such as some types of antidepressants.

Q: What is the risk of developing a low hormone condition like Adrenal Insufficiency while taking Opana ER?

Regulatory documents list adrenal insufficiency as a rare but serious risk associated with opioid use. This condition occurs when the adrenal glands do not produce enough of the stress hormone cortisol. This risk is important to note and is included in the official safety profile for the medication.

Q: Can Opana ER interact with over-the-counter sleep aids or cold medicines?

Official warnings advise against concurrent use with any other substance that causes central nervous system (CNS) depression. This additive effect, which can result in profound sedation or breathing problems, may occur with certain common over-the-counter products, such as specific sleep aids or cold medicines.

Q: What symptoms are associated with discontinuing Opana ER?

If a person who is physically dependent stops Opana ER abruptly, opioid withdrawal symptoms are likely to occur. Official information states these symptoms can include physical effects like agitation, sweating, yawning, muscle aches, and increased heart rate. For this reason, regulatory documents advise that therapy is generally tapered gradually to prevent the onset of withdrawal symptoms.

Q: What is the risk of addiction when Opana ER is used exactly as prescribed?

According to the Boxed Warning, Opana ER carries a risk of addiction, abuse, and misuse. Official documents state that this risk exists even when the medication is used exactly as prescribed by a healthcare professional.

Q: Is Opana ER safe for use by elderly patients?

Official information indicates that elderly patients are at increased risk for life-threatening side effects, including respiratory depression, and may experience more unwanted effects such as confusion or dizziness. Due to age-related changes in organ function, patients in this population are noted as requiring close monitoring and potential dose reduction.

Q: Is Opana ER suitable for patients with a history of seizures?

Regulatory documents state that Opana ER is noted as requiring caution in patients with a history of seizures. This caution is advised because opioids are described as potentially making certain seizure conditions worse.

Q: Is the brand name Opana ER still available for prescription?

The manufacturer of the brand name Opana ER voluntarily removed the product from the market in 2017. However, generic versions of the medicine, which contain oxymorphone extended-release tablets, are available for prescription.

Q: Why did the FDA request the manufacturer withdraw the original Opana ER formulation from the market in 2017?

In 2017, the FDA requested the withdrawal of a reformulated version of Opana ER from the market. This request was made because post-marketing data showed a concerning shift in the drug's abuse towards injection, which was linked to outbreaks of serious diseases like HIV and Hepatitis C.

Q: How does the potency of oxymorphone in Opana ER compare to that of morphine or other common opioids?

The active ingredient in Opana ER, oxymorphone, is considered a potent mu-opioid receptor agonist. Regulatory information indicates that its intrinsic analgesic potency is higher than that of morphine.

Q: Does the medication work immediately or does it require time to build up in the system?

As an extended-release (ER) formulation, the medication is designed to provide sustained and continuous pain relief over a 12-hour dosing interval, rather than immediate, rapid relief. It is intended to maintain a stable level of the medicine in the body for consistent, round-the-clock pain management.

Q: Are there specific lung or breathing conditions that prevent the use of Opana ER?

Official product information states that use is contraindicated (prohibited) in patients with significant respiratory depression or acute or severe bronchial asthma. Caution is also noted for individuals who have other severe lung or breathing problems, such as severe Chronic Obstructive Pulmonary Disease (COPD).

Q: What makes Opana ER different from other common extended-release opioids?

Opana ER contains oxymorphone, which is chemically defined as a semisynthetic opioid and a mu-opioid agonist. Its formulation, which historically included unique design features to help discourage non-oral misuse, sets it apart from common extended-release opioids containing different active ingredients like oxycodone or morphine.

How to Store and Dispose of Opana ER?

Opana ER (oxymorphone extended-release) must be stored and disposed of according to specific regulatory guidelines to ensure product stability and prevent misuse or accidental exposure.

Storage and Handling Requirements

Storage Factor	Official Requirement
Temperature	Store at 25 C (77 F); acceptable excursions between 15 C and 30 C (59 F and 86 F).
Container/Environment	Keep the bottle tightly closed in the original container, protected from moisture.
Security	Must be kept in a secure place, out of the sight and reach of children and others in the home.

Disposal Instructions

When Opana ER is no longer needed, it must be disposed of promptly. The preferred method is to use a drug take-back program. If a program is not immediately available, the tablets must be immediately flushed down the toilet. This method is explicitly authorized by regulatory bodies to prevent accidental ingestion or diversion of this medication.